TECENTRIQ HYBREZA
GrowthmAbBLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECENTRIQ HYBREZA is a fixed-dose combination of atezolizumab (a PD-1 blocking antibody) and hyaluronidase-tqjs, enabling subcutaneous delivery of the checkpoint inhibitor. It is indicated for cancers where PD-1 blockade is therapeutic, with the hyaluronidase component improving patient convenience by reducing infusion time and enabling self-administration. The drug works by releasing PD-1 checkpoint brakes on T cells, restoring anti-tumor immunity.
Growth
Early-stage growth phase product recently approved; commercial team is scaling market penetration against established competitors in a crowded PD-1 checkpoint class.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TECENTRIQ HYBREZA positions you in a high-visibility oncology franchise amid intense competitive pressure; career trajectory depends on successful market capture against established players. Early-stage launch roles offer visibility and upside potential, but eventual lifecycle decline (typical for biologic combinations) means strategic transition planning is essential 3–5 years post-launch.
Brand Manager
Worked on TECENTRIQ HYBREZA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.